Особливості терапії передменструального синдрому у жінок з ендометріозом

In: 2309-4117 · 2014 · W7112889779
OA: green CC0
🔓 Open OA copy Full text JSON View on OpenAlex
⚙ AI-generated summary by qwen3.7-flash, 2026-10-06 ⓘ

Magnicum administered from day 14 to 28 of the menstrual cycle for three months showed comparable effectiveness to dydrogesterone in treating premenstrual syndrome in women with endometriosis, particularly for edematous and neuropsychiatric symptoms.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-10-06 · read from full text ⓘ

This study evaluated the efficacy of Magnicum, a magnesium and vitamin B6 supplement, compared to dydrogesterone for treating premenstrual syndrome in 45 women aged 19 to 40 with moderate symptoms. The researchers administered the supplement from days 14 to 28 of the menstrual cycle over three months and found its effectiveness comparable to hormonal therapy, particularly for edematous forms and specific neuropsychiatric or cephalgic symptoms. The paper explicitly states that the treatment regimens were similar in outcome, highlighting the potential utility of magnesium-based interventions for this patient group. This paper is centrally about endometriosis — specifically investigating therapeutic options for comorbid premenstrual syndrome in women diagnosed with the condition.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

A study on the effectiveness of treatment of premenstrual syndrome in patients with endometriosis was performed. It included 45 women of reproductive age from 19 to 40 years with moderate severity of premenstrual syndrome. Authors of this study suggested that treatment regimens 1 or 2 tablets Magnicum 3 times a day from the 14th to the 28th day of the menstrual cycle for three months were comparable in effectiveness with dydrogesterone treatment, especially for the edematous form and some symptoms of neuropsychiatric and cephalgic form of premenstrual syndrome.
Full text 2,496 characters · extracted from oa-html · click to expand
Therapy features of premenstrual syndrome in women with endometriosis DOI: https://doi.org/10.18370/2309-4117.2014.17.80-86Keywords: premenstrual syndrome, endometriosis, magnesium, vitamin B6, MagnicumAbstract A study on the effectiveness of treatment of premenstrual syndrome in patients with endometriosis was performed. It included 45 women of reproductive age from 19 to 40 years with moderate severity of premenstrual syndrome. Authors of this study suggested that treatment regimens 1 or 2 tablets Magnicum 3 times a day from the 14th to the 28th day of the menstrual cycle for three months were comparable in effectiveness with dydrogesterone treatment, especially for the edematous form and some symptoms of neuropsychiatric and cephalgic form of premenstrual syndrome. References - Tatarchuk, T.F. Ventskovskaya, I.B. Shevchuk, T.V. «Premenstrual syndrome is an interdisciplinary problem.» Art of treatment,4(010) (2004):36-43. - Peresada, O.A. «Premenstrual syndrome: pathogenesis, clinical manifestations, treatment.» Medical News,8(2010):15-18. - Prilepskaya, V.N. Mezhevitinova, E.A. Sasunova, R.A. Ivanova, E.V. «Role of magnesium in the pathogenesis of premenstrual syndrome.» Russian Obstetrician and Gynecologist Gazette,3(2012). - Mayorov, M.V. Zhuchenko, S.I. «Using of magnesium drugs in outpatient gynecology.» Medical aspects of women’s health,1(2011):14 -18. - Gonda, X. Telek, T. Juhasz, G. Lazary, J. Vargha, A. Bagdy, G. «Patterns of mood changes throughout the reproductive cycle in healthy women without premenstrual dysphoric disorders.» Prog. Neuropsychopharmacol. Biol. Psychiatry,32(8)(2008):1782-1788. Downloads Published How to Cite Issue Section License Copyright (c) 2014 Н. Ф. Захаренко, В. П. Ковбасий, И. П. Маноляк This work is licensed under a Creative Commons Attribution 4.0 International License. Authors who publish with this journal agree to the following terms: - Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. - Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK